Bristol Myers Squibb vs ELI LILLY (BMY vs LLY)
Side by side from their SEC filings: revenue, margins, growth, returns and valuation, plus short interest, insider activity and institutional ownership.
ELI LILLY is the larger company by revenue ($65.2B vs $48.2B) and market value ($1.0T vs $136.7B). ELI LILLY has grown revenue faster over the last 4 fiscal years (+130.2% cumulative vs +3.9%). Bristol Myers Squibb trades at the lower trailing P/E (14.7x vs 38.9x).
About Bristol Myers Squibb
Bristol Myers Squibb is a biopharmaceutical company that discovers, develops, manufactures, markets, and sells innovative medicines for serious diseases. Its main products include biologics, small molecule drugs, CAR-T cell therapies, and radiopharmaceuticals used to treat conditions such as cancer, autoimmune diseases, cardiovascular and neurological disorders. The company serves patients worldwide through wholesalers, distributors, specialty pharmacies, hospitals, clinics, and government agencies.
About ELI LILLY
Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products worldwide. Its main products include treatments for diabetes, oncology, immunology, and neuroscience conditions. The company serves healthcare providers, wholesalers, pharmacies, hospitals, and patients in approximately 90 countries.
Head to head (BMY FY2025 vs LLY FY2025)
| Metric | BMYFY2025 | LLYFY2025 |
|---|---|---|
| Revenue | $48.19B | $65.18B |
| Revenue growth (YoY) | -0.2% | 44.7% |
| Gross margin | 71.1% | 83.0% |
| Operating margin | — | — |
| Net margin | 14.6% | 31.7% |
| Net income | $7.05B | $20.64B |
| Diluted EPS | $3.46 | $22.95 |
| FCF margin | 26.7% | — |
| ROE | 38.1% | 77.8% |
| Long-term debt / equity | 2.32× | 1.54× |
| Market cap | $136.70B | $1.03T |
| P/E | 14.7× | 38.9× |
Fundamentals are from each company’s SEC filings (BMY FY2025, LLY FY2025). ROE is net income over fiscal-year-end equity; long-term debt / equity counts non-current term debt only. P/E and market cap are derived from stored market prices, last retrieved on a rolling basis and typically within the past week.
Five-year trend (as reported)
| Revenue | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| BMY | $46.38B | $46.16B | $45.01B | $48.30B | $48.19B |
| LLY | $28.32B | $28.54B | $34.12B | $45.04B | $65.18B |
Peer standing
Where each company ranks among the 198 pharmaceutical companies, on the same scale. Each figure is ranked only against peers that report it. Percentiles describe position in the distribution, not a rating.
| Metric | BMY | LLY |
|---|---|---|
| Gross margin | 71.1%57th percentile of 69 | 83.0%82nd percentile of 69 |
| Net margin | 14.6%76th percentile of 122 | 31.7%86th percentile of 122 |
| Revenue growth (YoY) | -0.2%34th percentile of 187 | +44.7%72nd percentile of 187 |
| ROE | 38.1%93rd percentile of 167 | 77.8%99th percentile of 167 |
| P/E | 14.7×44th percentile of 60 | 38.9×78th percentile of 60 |
| Long-term debt / equity | 2.32×90th percentile of 64 | 1.54×89th percentile of 64 |
| Short interest (days to cover) | 3.48d29th percentile of 197 | 2.11d18th percentile of 197 |
Short interest
| FINRA settlement data | BMY | LLY |
|---|---|---|
| Shares sold short | 45.9M | 6.6M |
| Change vs prior settlement | -12.4% | -28.0% |
| Days to cover | 3.48 | 2.11 |
| As of settlement | 2026-08-14 | 2026-08-14 |
Source: FINRA Consolidated Short Interest. FINRA is the owner and source of the FINRA-supplied data; republishing or redistributing it is not permitted. Not presented as a percentage of float. No FINRA endorsement of this product is implied.
Insider activity (last 90 days)
| Form 4 activity (codes P/S) | BMY | LLY |
|---|---|---|
| Buys | 0 | 0 |
| Sells | 1 ($33,750) | 4 ($18.8M) |
Non-derivative purchases (code P) and sales (code S) reported on SEC Form 4, which may be open-market or private (grants, exercises and tax withholding excluded). For context, about 15% of covered companies saw any reported insider purchase (code P) in a 90-day window.
Held by the same investors
7 tracked 13F managers hold both Bristol Myers Squibb and ELI LILLY as of their latest quarterly filings: AQR Capital Management, Citadel Advisors, D. E. Shaw, Dodge & Cox, Gotham Asset Management, Millennium Management, Two Sigma Investments. See which superinvestors hold your own portfolio with the smart money checker.
Go deeper
ABBV vs BMYABT vs BMYBMY vs JNJBMY vs MRKBMY vs PFEBMY vs VRTXAll pharmaceutical stocks →All comparisons →
Track BMY and LLY
Get an alert when either company files something material, see which superinvestors own them, and ask their filings a question with cited answers.
Start monitoring freeIncludes one free filing-grounded research answer. Or check your whole portfolio, no account needed.
Data sourced from SEC EDGAR. Figures are as-reported and may be unaudited or restated; verify against the source filings before relying on them. Comparisons are descriptive (higher or lower on a reported figure), not a rating or a recommendation. Informational only. Not investment advice.